BioSpace News Archive

Melbourne, Australia; 30 August 2018: Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX: CYP) is pleased to announce that CYP-001, its lead Cymerus™ mesenchymal stem cell (MSC) product candidate, met all clinical endpoints in a Phase 1 trial for the treatment of steroid-resistant acute graft-versus-host disease (GvHD).

Baylis Medical Company announced the official commercial launch of its SureFlex® Steerable Guiding Sheath.

Technavio has announced their latest pipeline analysis report on the drug pipeline for laryngeal cancer. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat laryngeal cancer.

Digital bracelets to benefit Alex’s Lemonade Stand Foundation

Orexo AB (publ.) today announces that the US Court of Appeals for the Federal Circuit found Orexo’s long term Zubsolv patent US 8,940,330 to be valid, and reversed the invalidity decision previously rendered by the District Court of Delaware in November 2016.

Genesys Spine is pleased to announce the FDA clearance of our latest product line, the AIS-C Stand-Alone System.

Seven Bridges today announced the launch of the new Kids First Data Resource Portal with the Gabriella Miller Kids First Data Resource Center (DRC) at the Center for Data Driven Discovery in Biomedicine (D3b) at Children’s Hospital of Philadelphia.

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it received Health Canada approval of Xydalba™ (dalbavancin hydrochloride), the first and only one-dose treatment option for acute bacterial skin and skin structure infections (ABSSSI) in adults and available in Canada

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, today announced the closing of its previously announced underwritten public offering of 4,600,000 shares,

Cross Country Healthcare, Inc. today announced that William J. Grubbs intends to retire as President, Chief Executive Officer and a member of the Board of Directors of the Company when his contract expires at the end of March 2019 or, if earlier, the date the Board of Directors appoints a new Chief Executive Officer.